221 related articles for article (PubMed ID: 25333846)
21. A common ancestral DNMT3A-mutated preleukemic clone giving rise to AML and MDS in an adolescent girl.
Göhring G; Thomay K; Schmidt G; Ripperger T; Xu M; Wittner N; Chao MM; Baumann I; Niewisch M; Reinhardt D; Klingebiel T; Thol F; Schlegelberger B; Niemeyer CM
Leuk Lymphoma; 2017 Mar; 58(3):718-721. PubMed ID: 27892742
[No Abstract] [Full Text] [Related]
22. Biology and clinical features of myeloid neoplasms with inv(3)(q21q26) or t(3;3)(q21q26).
Sperr W; Valent P
Leuk Lymphoma; 2007 Nov; 48(11):2096-7. PubMed ID: 17990175
[No Abstract] [Full Text] [Related]
23. Recurrent mutations in multiple components of the SWI/SNF complex in myelodysplastic syndromes and acute myeloid leukaemia.
Yao H; Huo L; Ping N; Liu H; Li H; Ding Z; Shen H; Xie J; Qiu Q; Ma L; Jiang A; Wang Q; Wu D; Yang X; Song Y; Chen S
Br J Haematol; 2022 Jan; 196(2):441-444. PubMed ID: 34535894
[No Abstract] [Full Text] [Related]
24. High-throughput mutational screening adds clinically important information in myelodysplastic syndromes and secondary or therapy-related acute myeloid leukemia.
Karimi M; Nilsson C; Dimitriou M; Jansson M; Matsson H; Unneberg P; Lehmann S; Kere J; Hellström-Lindberg E
Haematologica; 2015 Jun; 100(6):e223-5. PubMed ID: 25769547
[No Abstract] [Full Text] [Related]
25. Therapeutic epigenetics: an emerging clinical approach to hematologic malignancies.
Clin Adv Hematol Oncol; 2005 Mar; 3(3 Suppl 1):1-10; quiz 11-2. PubMed ID: 21438190
[No Abstract] [Full Text] [Related]
26. Does monosomy 5 really exist in myelodysplastic syndromes and acute myeloid leukemia?
Galván AB; Mallo M; Arenillas L; Salido M; Espinet B; Pedro C; Florensa L; Serrano S; Solé F
Leuk Res; 2010 Sep; 34(9):1242-5. PubMed ID: 20362335
[TBL] [Abstract][Full Text] [Related]
27. Oñate G, Bataller A, Garrido A, et al; CETLAM (Spanish Cooperative Group for the Diagnosis and Treatment of Acute Myeloid Leukemia and Myelodysplastic Syndromes). Prognostic impact of DNMT3A mutation in acute myeloid leukemia with mutated NPM1. Blood Adv. 2022;6(3):882-890.
Blood Adv; 2023 Mar; 7(5):875. PubMed ID: 36917130
[No Abstract] [Full Text] [Related]
28. Epigenetic changes in therapy-related MDS/AML.
Voso MT; D'Alò F; Greco M; Fabiani E; Criscuolo M; Migliara G; Pagano L; Fianchi L; Guidi F; Hohaus S; Leone G
Chem Biol Interact; 2010 Mar; 184(1-2):46-9. PubMed ID: 19874806
[TBL] [Abstract][Full Text] [Related]
29. Involvement of a member of the histone cluster 1 at 6p21 in NUP98-positive MDS/AML.
Di Giacomo D; Pierini V; La Starza R; Borlenghi E; Pellanera F; Lema Fernandez AG; Bellotti D; Lamorgese C; Rossi G; Mecucci C
Leuk Lymphoma; 2017 Nov; 58(11):2765-2767. PubMed ID: 28482724
[No Abstract] [Full Text] [Related]
30. Epigenetic deregulation in myeloid malignancies.
Meldi KM; Figueroa ME
Transl Res; 2015 Jan; 165(1):102-14. PubMed ID: 24813528
[TBL] [Abstract][Full Text] [Related]
31. Clinical and functional characterization of telomerase variants in patients with pediatric acute myeloid leukemia/myelodysplastic syndrome.
Tomlinson CG; Sasa G; Aubert G; Martin-Giacalone B; Plon SE; Bryan TM; Bertuch AA; Gramatges MM
Leukemia; 2021 Jan; 35(1):269-273. PubMed ID: 32313107
[No Abstract] [Full Text] [Related]
32. Epigenetics in myeloid malignancies.
Deneberg S
Methods Mol Biol; 2012; 863():119-37. PubMed ID: 22359290
[TBL] [Abstract][Full Text] [Related]
33. Emerging importance of mutational analysis in myelodysplastic syndrome and acute myelogenous leukemia.
Gerds AT; Walter MJ; Scott BL
Biol Blood Marrow Transplant; 2013 Jan; 19(1 Suppl):S33-7. PubMed ID: 23290440
[No Abstract] [Full Text] [Related]
34. [Association between multiple myeloma and acute myeloid leukemia secondary to myelodysplastic syndrome].
Jennane S; Eddou H; Mahtat el M; Konopacki J; Souleau B; Malfuson JV; Foissaud V; de Revel T
Ann Biol Clin (Paris); 2013; 71(5):581-4. PubMed ID: 24113443
[TBL] [Abstract][Full Text] [Related]
35. [Epidemiology of leukemia and MDS among atomic bomb survivors in Hiroshima and Nagasaki suggests how abnormal epigenetic regulation contributes to leukemogenesis].
Inaba T
Rinsho Ketsueki; 2009 Oct; 50(10):1548-52. PubMed ID: 19915365
[No Abstract] [Full Text] [Related]
36. Translocation (8;21)(q22;q22) and the myelodysplastic syndrome.
Kwong YL; Wong KF
Leuk Res; 1995 Sep; 19(9):675-7. PubMed ID: 7564479
[No Abstract] [Full Text] [Related]
37. Clinical implications of genome-wide DNA methylation studies in acute myeloid leukemia.
Li Y; Xu Q; Lv N; Wang L; Zhao H; Wang X; Guo J; Chen C; Li Y; Yu L
J Hematol Oncol; 2017 Feb; 10(1):41. PubMed ID: 28153026
[TBL] [Abstract][Full Text] [Related]
38. Lytic bone disease as the presenting feature of Philadelphia-positive, derivative chromosome 7 myelodysplasia progressing to acute myeloid leukaemia.
Tucker D; Hamilton MS; Kerr JP; Wickham C; Hunter H
Gene; 2013 Feb; 515(1):239. PubMed ID: 23431568
[No Abstract] [Full Text] [Related]
39. Optical Genome Mapping in MDS and AML as tool for structural variant profiling-comment and data update on Yang et al.: "High-resolution structural variant profiling of myelodysplastic syndromes by optical genome mapping uncovers cryptic aberrations of prognostic and therapeutic significance".
Vangala DB; Nilius-Eliliwi V; Gerding WM; Schroers R; Nguyen HP
Leukemia; 2023 Jan; 37(1):248-249. PubMed ID: 36434063
[No Abstract] [Full Text] [Related]
40. Risk assessment according to IPSS-M is superior to AML ELN risk classification in MDS/AML overlap patients defined by ICC.
Huber S; Baer C; Hutter S; Dicker F; Fuhrmann I; Meggendorfer M; Pohlkamp C; Kern W; Haferlach T; Haferlach C; Hoermann G
Leukemia; 2023 Oct; 37(10):2138-2141. PubMed ID: 37573403
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
